In the News
Intelligent Technology Brings Companies To A New Moment Of Truth
GNS Healthcare used its causal AI platform to not only predict which patients with metastatic colorectal cancer will respond to which treatments, but why…
read more
Colin Hill Opening Keynote at the Annual Merck Technology Symposium 2022
Our CEO, Colin Hill gave an opening keynote entitled “Can Virtual Patients Unlock The Biological Complexity Of Human Disease And Drive the Next Wave Of Breakthrough Drugs?” in this year annual Merck technology symposium…
read more
How AI is helping “drug hunters” succeed – GNS Co-founder, Iya Khalil talk on CNN
GNS Co-Founder Iya Khalil weighed in on how using AI and big data will transform medicine.
read moreEvents
GNS Announces Oral Poster Presentation and Abstract at ASH
GNS today announced an oral poster presentation and an abstract highlighting insight from the Gemini Digital Twin model in Multiple Myeloma
read more
GNS Announces Oral Poster Presentation and Abstract at CTAD
GNS today announced an oral poster presentation and an abstract highlighting insight from the Gemini Digital Twin model in Alzheimer Disease.
read more
GNS Attending BioTechX Europe’s Largest Congress
BioTechX is Europe’s largest congress covering latest breakthroughs in pharmaceutical development and healthcare…
read morePress Releases
GNS Announces Abstract and Oral Poster Presentation at CTAD & ASH, 2022 Annual Conferences
GNS, the leader in the application of Causal AI and simulation and “Digital Twins” to discover new drugs, today announced two abstracts and two oral poster presentations highlighting insight from the Gemini Digital Twin models in Alzheimer’s Disease and Multiple Myeloma will be included at the Clinical Trials on Alzheimer’s Disease conference (CTAD) in San Francisco and the American Society of Hematology (ASH) in New Orleans…
read moreGNS Appoints John Maraganore as Chair of the Board
GNS, the leader in the application of Causal AI and simulation and “Digital Twins” to discover new drugs, today announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, has been appointed as the new GNS Chair of the Board…
read moreGNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
GNS and Servier, today announced a collaboration to advance drug discovery, translational, and clinical development efforts in Multiple Myeloma (MM).
read more